Abstract 30P
Background
Accelerated partial breast irradiation (APBI) is now widely adopted in the treatment with low risk early breast cancer worldwide. Both stereotactic body radiotherapy (SBRT) using Cyberknife (CK) and interstitial brachytherapy (IB) are available for APBI. This study was designed to compare the dosimetric characteristics of organ at risk and the clinical outcome between two different techniques.
Methods
Forty-four patients with left sided early breast cancer treated by APBI in our institute were reviewed. The radiation doses are 30Gy in 5 fractions, in 5 consecutive days using CK and 34Gy in 10 fractions, BID in 5 consecutive days using IB. Dosimetric parameters of OARs were calculated for both techniques and compared. The preliminary clinical outcomes include the local recurrence rate, acute toxicity (CTCAE V5.0) and cosmetic evaluation (Harvard scales) were analyzed.
Results
The median follow up time of CK group and IB group were 19.3 months (range: 4.5∼48.4 months) and 53.5months, respectively. Two patients from IB group had sentinel lymph node micrometastasis in the final pathology report and whole breast irradiation plus regional lymph node irradiation was added subsequently. One patient from IB group had regional lymph node recurrence during follow up and underwent surgery and re-irradiation with stable disease now. Most common acute toxicity was grade 1 radiation dermatitis. Neither radiation pneumonitis nor heart events were noted during the follow up. Multiple small scars left for more than 6 months in a few patients after interstitial brachytherapy. Patients reported cosmetic results according to Harvard scales, with “good” score in most patient of IB group and no cases described as “poor”. Dosimetric parameters of OAR showed the heartV150cGy of CK and IB was 23.5% and 59.2%. The mean heart dose of CK and IB were 117.1cGy and 215.6cGy.
Conclusions
APBI by SBRT using CK is a non-invasive procedure and has better dose-sparing effect on the heart. There were less risks of wound infection or delayed wound healing when using CK. Since no small scars left on the breast when using CK, better cosmetic outcome is expected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract